Literature DB >> 31303394

Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease.

Joel Ohm1, Paul Hjemdahl2, Per H Skoglund3, Andrea Discacciati4, Johan Sundström5, Kristina Hambraeus6, Tomas Jernberg7, Per Svensson8.   

Abstract

BACKGROUND: Low density lipoprotein cholesterol (LDL-C) goals post-myocardial infarction (MI) are debated, and the significance of achieved blood lipid levels for predicting a first recurrent atherosclerotic cardiovascular disease (rASCVD) event post-MI is unclear.
METHODS: This was a cohort study on first-ever MI survivors aged ≤76 years attending 4-14 week revisits throughout Sweden 2005-2013. Personal-level data was collected from SWEDEHEART and linked national registries. Exposures were quintiles of LDL-C, high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglycerides (TGs) at the revisit. Group level associations with rASCVD (nonfatal MI or coronary heart disease death or fatal or nonfatal ischemic stroke) were estimated in Cox regression models. Predictive capacity was estimated by differences in C-statistic, integrated discriminatory improvement, and net reclassification improvement when adding each blood lipid to a validated risk prediction model.
RESULTS: 25,643 patients, 96.9% on statin therapy, were followed during a mean of 4.1 years. rASCVD occurred in 2173 patients (8.5%). For LDL-C and TC, moderate associations with rASCVD were observed only in the 5th vs. the lowest (referent) quintiles. For TGs and HDL-C increased risks were observed in quintiles 3-5 vs. the lowest. Minor predictive improvements were observed when lipid fractions were added to the risk model but the discrimination overall was poor (C-statistics <0.6).
CONCLUSIONS: Our data question the importance of LDL-C levels achieved at first revisit post-MI for decisions on continued treatment intensity considering the weak association with rASCVD observed in this post-MI cohort.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lipid levels; Low density lipoprotein cholesterol (LDL-C); Myocardial infarction; Recurrence; Risk prediction; Secondary prevention

Year:  2019        PMID: 31303394     DOI: 10.1016/j.ijcard.2019.07.001

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial.

Authors:  Samaneh Tabaee; Amirhossein Sahebkar; Tayebe Aghamohammadi; Manizhe Pakdel; Maryam Dehabeh; Reza Sobhani; Mona Alidadi; Muhammed Majeed; Seyed Reza Mirhafez
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Cardiovascular Family History Increases the Risk of Disease Recurrence After a First Myocardial Infarction.

Authors:  Agnes Wahrenberg; Ralf Kuja-Halkola; Patrik K E Magnusson; Henrike Häbel; Anna Warnqvist; Kristina Hambraeus; Tomas Jernberg; Per Svensson
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 5.501

3.  Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.

Authors:  Ali Allahyari; Tomas Jernberg; Emil Hagström; Margrét Leosdottir; Pia Lundman; Peter Ueda
Journal:  Eur Heart J       Date:  2020-10-21       Impact factor: 29.983

4.  Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.

Authors:  Ichiro Komiya; Akira Yamamoto; Suguru Sunakawa; Tamio Wakugami
Journal:  Lipids Health Dis       Date:  2021-02-20       Impact factor: 3.876

5.  Inverse Association between High-Density Lipoprotein Cholesterol and Adverse Outcomes among Acute Ischemic Stroke Patients with Diabetes Mellitus.

Authors:  Guoliang Hu; Yuesong Pan; Mengxing Wang; Xia Meng; Yong Jiang; Zixiao Li; Hao Li; Yongjun Wang; Yilong Wang
Journal:  Biomedicines       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.